Search by Letter: ABCDEFGHIJKLMNOPQRSTUVWXYZ

Femynor Review


Femynor is a monophasic low dose birth control means. This birth control drug contains ethinyl estradiol and norgestimate devoted to taking the pregnancy occurrence under control.

Contents:

 

Indications for use

Contraception

Mechanism of action

Femynor intake results in an abrupt reduction in the secretion of gonadoliberin. As a result, the production of FSH is inhibited by the pituitary gland, which, in turn, decelerates the growth and maturation of the follicles in the ovaries. Progestin suppresses the release of LH by the pituitary gland which fosters the ovulation suppression. Moreover, ethinyl estradiol and norgestimate magnify the cervical mucus viscosity, which prevents the penetration of spermatozoa into the uterine cavity. Under the influence of combined oral contraceptive drugs, endometrium changes take place which complicates a fertilized egg implantation.

Mode of application and dosage

Femynor is prescribed as a 28 days-course. The breaks are not necessary. The drug should be taken approximately at the same time washed down with a small amount of water. The correct order is specified on the blister. The next package should be started when the latest placebo pill is taken.

Overdose:

The cases of an overdose are not enormous. The most common signs of this condition are vomiting, nausea, and vaginal bleeding. The specific therapy is not required. The gastric lavage is prescribed as the main way to excrete the hormones from the blood plasma.

Contraindications

Femynor (ethinyl estradiol and norgestimate) has a number of contraindications. The doctor should be informed about the following medical conditions:

  • venous thrombosis, deep vein thrombosis, pulmonary thromboembolism including in the medical history;
  • arterial thrombosis including acute cerebrovascular accident, myocardial infarction, retinal artery thrombosis or precursors of thrombosis inclusively of angina pectoris or transient ischemic attack found in the medical history;
  • thromboembolism;
  • the presence of serious or multiple risk factors for arterial thrombosis;
  • arterial hypertension;
  • diabetes mellitus exacerbated by vascular disease;
  • genetic dyslipoproteinemia;
  • hypersensitivity to any drug components;
  • migraine with aura;
  • cerebrovascular disorders;
  • carcinoma of the breast and endometrium, other estrogen-dependent formations;
  • hepatic failure;
  • hemolytic anemia;
  • sickle-cell anemia;
  • benign or malignant hepatic tumors;
  • otosclerosis;
  • cholestatic jaundice during pregnancy;
  • coronary cardiac disease;
  • vaginal bleeding of unspecified genesis;
  • a period after menopause.
  • age up to 18 years;
  • postpartum period (4 weeks);
  • pregnancy and breastfeeding.

 

Side effects

  • Cardiovascular system: arterial hypertension, myocardial infarction, cerebrovascular accident, deep vein thrombosis, arterial thromboembolism, pulmonary or other thromboembolism, edema.
  • Tumors: benign and malignant hepatic tumors, cervical and breast cancer.
  • Hepatobiliary system: cholestatic jaundice, Budd-Chiari syndrome, intrahepatic cholestasis, cholelithiasis.
  • Gastrointestinal tract: nausea, vomiting, abdominal pain, flatulence, colitis, anorexia.
  • Genital organs: intermenstrual bleeding, spotting, amenorrhea, menstrual cycle changes, increase in the uterine fibroids size, vaginal candidiasis, the cervical secretion increase, cervical erosion, decreased libido, premenstrual syndrome, temporary infertility after the end of the drug.
  • Breast glands: soreness and sensation of tension, galactorrhea, tenderness, increase in size, decrease in lactation when taken immediately after birth.
  • Skin conditions: erythema nodosum, skin rash, chloasma, exudative erythema, acne, seborrhea, alopecia, hirsutism, pigment face spots, hypertrichosis, pemphigoid (gestational herpes), melasma.
  • Visual organs: cataract, optic nerve lesion, change in corneal curvature, intolerance to wearing contact lenses.
  • Central nervous system: headache, mood changes, irritability, depression, chorea, dizziness, migraine.
  • Metabolism: fluid body retention, increase or decrease in body weight, decreased glucose tolerance, changes in appetite.
  • Renal condition: decreased kidney function, hemolytic-uremic syndrome.
  • Others: kidney disease, a decrease in libido.

 

Interactions

When taking Hypericum perforatum, barbiturates, carbamazepine, phenytoin, sulfonamides, derivatives of pyrazolone, rifampicin together with Femynor there is an increase in the steroid hormones’ metabolism.

When taken some antibiotics (for example, ampicillin or tetracycline) it is necessary to use additional backup means to prevent an unwanted pregnancy.

Some protease inhibitors and some antiretroviral drugs are able to increase (for example, indinavir) or decrease (for example, ritonavir) the level of hormones in blood plasma.

What if I miss a dose?

If you are late in applying the active pill for less than 24 hours, the chance to become pregnant is lower than average. Use the pill at the moment you understand it and continue the course.

If you are late in applying the pills for more than 24 hours, the chance to become pregnant becomes higher than average. It is necessary to use other protective methods not to become pregnant.

Femynor and pregnancy

Femynor is contraindicated during pregnancy and breastfeeding. Women should discontinue the application of birth control when the diagnosis “pregnancy” is established. If you are born a child you cannot елу birth control pills as it may penetrate the breast milk influencing the newborn health.

Feedback Form

Name
Rating
Review Content